Teijin Pharma and TransThera Biosciences have entered into a strategic collaboration agreement for the research and development of drugs in the areas of oncology and inflammatory diseases.
The companies will establish a drug discovery collaboration of multiple drug targets with the goal of acquiring compounds as candidates for drug development based on the targets and compounds found by Teijin Pharma, and share the research outcomes in both Japan and China. The two companies will share a global development license when the compound enters the development stage and consider the joint development and launch of drugs in Japan, China, and rest of the world.
“We are delighted to create innovative new drugs together with TransThera,” said Ichiro Watanabe, president of Teijin Pharma. “Under the Teijin Group’s current medium-term management plan, we are contributing to sustainability by developing solutions for a demographic change and increased healthconsciousness. Launching new drugs will be a key factor in our implementation of this plan and we look forward to creating innovative new drugs together with TransThera.”
“I am very excited about the opportunity for TransThera to work with Teijin pharma, a leading R&D based company of high repute with admirable tradition,” said Frank Wu, CEO of TransThera. “Combining both companies’ outstanding target validation expertise, lead identification capability and development platform will certainly expedite the drug discovery process, hopefully bringing more drug therapies to the patients. I look forward to the productive work ahead.”
“I believe that this collaboration between Japanese and Chinese companies with a proactive mindset would set a new R&D model to increase R&D productivity and manage R&D risk,” Keiji Kawamoto, Senior Advisor of External Alliance of TransThera and co-founder of KoMong & Associates added. “I am pleased that my KoMong team members contribute significantly toward this exciting collaboration.”